Boston Scientific Corporation (NYSE:BSX) Short Interest Down 48.3% in June

Boston Scientific Corporation (NYSE:BSX) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 29,750,309 shares, a decrease of 48.3% from the May 31st total of 57,491,117 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 20,617,498 shares, the short-interest ratio is presently 1.4 days.

Boston Scientific Price Performance

BSX stock traded up $0.30 during trading on Wednesday, hitting $42.98. The company had a trading volume of 25,357,073 shares, compared to its average volume of 20,496,262. The company has a fifty day moving average price of $51.68 and a two-hundred day moving average price of $69.93. Boston Scientific has a fifty-two week low of $42.25 and a fifty-two week high of $109.50. The company has a market cap of $63.88 billion, a P/E ratio of 17.98, a P/E/G ratio of 0.82 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the business earned $0.75 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BSX shares. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Jefferies Financial Group lowered their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Citigroup dropped their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Finally, Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $83.36.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 9,800 shares of company stock worth $554,012 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BSX. Renaissance Group LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at $28,064,000. Rathbones Group PLC increased its position in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after purchasing an additional 477,680 shares during the period. Tounjian Advisory Partners LLC acquired a new stake in Boston Scientific in the fourth quarter worth about $1,477,000. Waycross Partners LLC bought a new stake in Boston Scientific during the 4th quarter worth about $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new position in Boston Scientific during the 3rd quarter valued at about $26,955,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific completed its POLARx Post Approval Study, adding fresh clinical data to its atrial fibrillation growth story and supporting the long-term outlook for its electrophysiology business. Boston Scientific’s POLARx Study Completion Adds Fresh Data to Atrial Fibrillation Growth Story
• Positive Sentiment: The company’s latest reported revenue growth remains strong, with Q1 sales up 11.6% year over year, which helps reinforce the durability of Boston Scientific’s core medtech franchise.
• Neutral Sentiment: Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an option to buy its TAVR system, a strategic move that could expand its structural heart pipeline over time. Boston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition Option
• Neutral Sentiment: Stifel lowered its price target to $65 from $75 but kept a Buy rating, while other analysts also trimmed earnings estimates only slightly; the cuts suggest some caution, but not a full deterioration in the long-term thesis. Stifel Cuts PT on Boston Scientific Corporation (BSX)- Here’s Why
• Negative Sentiment: Recent analyst commentary and social-media chatter focused on softer demand for the Watchman device, bundling pressure, and technical weakness near multi-year lows, which likely contributed to the stock’s decline. Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades
• Negative Sentiment: Boston Scientific also declined in the latest session despite a broader market gain, reflecting investor concern that recent analyst revisions and product-specific pressures may outweigh the company’s fundamental growth. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.